Last reviewed · How we verify
AGO Study Group — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
2 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| TCG | TCG | marketed | Fibrates | Cardiovascular | ||
| TC | TC | marketed | Chemotherapy combination regimen | Oncology |
Therapeutic area mix
- Cardiovascular · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Asan Medical Center · 1 shared drug class
- Children's Cancer Group, China · 1 shared drug class
- China Breast Cancer Clinical Study Group · 1 shared drug class
- Fujian Medical University · 1 shared drug class
- MIPO Clinic · 1 shared drug class
- Nanjing Yoko Biomedical Co., Ltd. · 1 shared drug class
- Ottawa Hospital Research Institute · 1 shared drug class
- Agendia · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for AGO Study Group:
- AGO Study Group pipeline updates — RSS
- AGO Study Group pipeline updates — Atom
- AGO Study Group pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AGO Study Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ago-study-group. Accessed 2026-05-13.